Assessment of brain delivery of a model ABCB1/ABCG2 substrate in patients with non-contrast-enhancing brain tumors with positron emission tomography

ConclusionsOur data suggest that the investigated brain tumors had an intact BBTB, which is impermeable to anticancer drugs, which are dual ABCB1/ABCG2 substrates. Therefore, effective drugs for antitumor treatment should have high passive permeability and lack ABCB1/ABCG2 substrate affinity.Trial registrationEuropean Union Drug Regulating Authorities Clinical Trials Database (EUDRACT), 2011-004189-13. Registered on 23 February 2012,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004189-13.
Source: EJNMMI Research - Category: Radiology Source Type: research

Related Links:

Dormancy and NKG2D system in brain metastases: Analysis of immunogenicity. Int J Mol Med. 2019 Dec 30;: Authors: Flüh C, Mafael V, Adamski V, Synowitz M, Held-Feindt J Abstract Patients with breast cancer (BC) and lung cancer (LC) are prone to developing brain metastases, which are associated with devastating prognoses. Dormant tumor cells, a population of non‑apoptotic quiescent cells and immunological escape mechanisms, including the Natural Killer Group 2 member D (NKG2D) receptor‑ligand system, represent potential mechanisms of tumor recurrence. To date, the immunological charac...
Source: International Journal of Molecular Medicine - Category: Molecular Biology Authors: Tags: Int J Mol Med Source Type: research
AbstractLaser interstitial thermal therapy (LITT) is an emerging modality to treat benign and malignant brain lesions. LITT is a minimally invasive method to ablate tissue using laser‐induced tissue heating and serves as both a diagnostic and therapeutic modality for progressive brain lesions. We completed a single‐center retrospective analysis of all patients with progressive brain lesions treated with LITT since its introduction at our center in August of 2015. Twelve patients have been treated for a total of 13 procedures, of which 10 patients had brain metastases and 2 patients had primary malignant gliomas. Biopsi...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Lung Cancer, Melanoma and Cutaneous Malignancies, Neuro-Oncology, Breast Cancer Brief Communications Source Type: research
on LM Abstract Quantification of radiation dose to normal tissue during radiotherapy is critical for assessing risk for radiotherapy-related late effects, including subsequent neoplasms (SNs). Case-control studies of SNs typically reconstruct absorbed radiation dose to the specific SN location using individual treatment parameters. A simplified method estimates the maximum prescribed target dose to the body region in which the SN arises. We compared doses and risk estimates from these methods using data from case-control studies of subsequent brain tumors (64 cases, 244 controls) and breast cancer (94 cases, 358 c...
Source: Radiation Research - Category: Physics Authors: Tags: Radiat Res Source Type: research
Patients with breast cancer or brain tumours could soon be diagnosed at a much earlier stage and potentially achieve better treatment outcomes if the promise of two UK studies holds true.Medscape News UK
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
ConclusionAlthoughmost brain tumors are metastases, primary brain tumors should be considered a possibility even in the presence of another source of metastases; especially if there is a lesion refractory to treatment.
Source: Interdisciplinary Neurosurgery - Category: Neurosurgery Source Type: research
AbstractToday, bio-medical efforts are entering the subcellular level, which is witnessed with the fast-developing fields of nanomedicine, nanodiagnostics and nanotherapy in conjunction with the implementation of nanoparticles for disease prevention, diagnosis, therapy and follow-up. Nanoparticles or nanocontainers offer advantages including high sensitivity, lower toxicity and improved safety —characteristics that are especially valued in the oncology field. Cancer cells develop and proliferate in complex microenvironments leading to heterogeneous diseases, often with a fatal outcome for the patient. Although antibo...
Source: BioDrugs - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 1 November 2019Source: Journal of Molecular BiologyAuthor(s): Vincenzo Alterio, Markus Kellner, Davide Esposito, Friederike Liesche-Starnecker, Silvia Bua, Claudiu T. Supuran, Simona Maria Monti, Reinhard Zeidler, Giuseppina De SimoneAbstract6A10 is a CA XII inhibitory monoclonal antibody, which was demonstrated to reduce the growth of cancer cells in vitro and in a xenograft model of lung cancer. It was also shown to enhance chemosensitivity of multiresistent cancer cell lines, and to significantly reduce the number of lung metastases in combination with doxorubicin in mice carrying huma...
Source: Journal of Molecular Biology - Category: Molecular Biology Source Type: research
How can you have a moonshot trying to cure cancer and not mention people dying of cancer?I believed the narrative that is pushed on women, that if you check your breasts and if you catch it early, you’re fine.ide class="right-rail__container right-rail__container--ad"> Lianne Kraemer had been living with metastatic breast cancer for more than a year when I met her in December 2017 at the Henry B. González Convention Center in San Antonio. Throughout the week, more than 7,000 doctors, scientists and pharmaceutical-company representatives would descend on the city for the country’s most impor...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Breast Cancer health Source Type: news
AbstractBackgroundImmune therapies targeting the programmed cell death receptor (ligand) 1 (PD-1/PD-L1) axis have shown remarkable activity in a variety of solid tumors. While substantial responses were observed in asymptomatic patients with brain metastases (BM), their clinical activity in primary brain tumors remains limited. In a cohort of adult brain tumor patients, we aimed to analyze soluble PD-L1 (sPD-L1) levels in patient plasma as a systemic marker of tumor - immune system interactions.MethodsWe obtained EDTA plasma from 55 glioblastoma, 26 lower-grade (WHO grade II - III) glioma (LGG), 17 meningioma and 43 BM pat...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
AbstractBackgroundSacituzumab govitecan (SG) is an antibody drug conjugate (ADC) that targets Trop-2 for the selective delivery of SN-38 to tumors. SG carries SN-38, a topoisomerase inhibitor active in the nanomolar range for most cells (including TNBC and GBM) and freely cross the blood brain barrier. SN-38 is conjugated to SG by a linker designated CL2A which is sensitive to acidic and conditions. SG was evaluated in a single-arm, multicenter trial with relapsed/refractory metastatic triple negative breast cancer (TNBC) with impressive results including a confirmed objective response rate of 30%, with responses occurring...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
More News: Brain | Brain Cancers | Brain Tumor | Breast Cancer | Cancer | Cancer & Oncology | Clinical Trials | Databases & Libraries | MRI Scan | Neurology | PET Scan | Radiology